KRX decides to delist Kolon TissueGene over fraudulent reporting

Kolon TissueGene, the U.S. subsidiary of South Korean drugmaker Kolon Life Science, is on the verge of being kicked out of the Korean bourse over the fraudulent reporting of its gene therapy drug Invo [전체본문 2020-11-05 10:30:00Z]